Member Info for TrickyEFC

Sell limits from NT to over 10mill now

I did

Biggest trade of the day so far and they printed it red 😂

That £6k is a buy

Mms they put it to no sells. Think they trying to spook people to sell

Someone over on advfn saying break out this week.

I concur as something has to give! £30 mill market cap for starters.

The disconnect has to stop this week

Along with the over count of issued shares they never seems to include us under the RNs news list

https://www.lse.co.uk/rns/aim.html

Those odds keep getting shorter 😯💪

Surely it can't be too far off given what is out in the public domain.

Surely someone must take a gamble before the odds reduce anymore and it's a banker.

Those who snooze lose

Bingo Bongo 💪💪🐴🐴

Bingo 😁😁

Cheers dv. Was also one that showed how other companies valued multiples of Solvonis that are yet to conclude stage 2 trails.

To put it into perspective this company is currently valued £15million less than Beto 😂😂😂😂

Chas long as they start off at £100 mill for the rights to svn01 as an independent product am good with that.

If they want the whole damn pipeline well then it would have to be a much bigger number.

Ha ha. Dv I was looking for the link that someone posted maybe nano or llama about the valuations of the other companies in comparison with Solvonis just to make sure am not getting carried away

1p values us at under £50mil and that we are currently not over 0.5p is absurd.

I can't get me head around this Fact

Surely it can't be too far off given what is out in the public domain.

Surely someone must take a gamble before the odds reduce anymore and it's a banker.

Those who snooze lose

On this board. I feel more convinced than before this is gonna be MASSIVE

OFT looks like it may have a fantastic future.

If they have previously approved this to be a commercial product then I think the FDA fast pathway at the start of the year for Svn002 is 💲💲💲💲

Sodium oxybate 175 mg/ml has been authorised nationally in Austria and Italy for use in alcohol‑dependent patients, under the name Alcover. In Austria, it is available as a syrup for the treatment of alcohol withdrawal syndrome and to support long-term abstinence under medical supervision along with psychotherapy (counselling) and social rehabilitation. In Italy, it is available as an oral solution for use as an adjuvant (add-on) medicine to control acute alcohol withdrawal syndrome.

Solvonis Therapeutics plc (LON: SVNS), ("Solvonis" or the "Company") an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that Awakn Life Sciences Corp. ("Awakn"), the company Solvonis plans to acquire, has reached a significant regulatory milestone. Awakn announced a positive outcome from a Pre-Investigational New Drug ("Pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") regarding AWKN-002, a proprietary oral thin film ("OTF") formulation of esketamine, designed for sublingual and buccal administration in combination with structured alcohol education. This drug candidate is being developed for the treatment of moderate to severe alcohol use disorder ("AUD") with a focus on U.S market.